Skip to main content
Clinical Trials/NCT01041989
NCT01041989
Active, Not Recruiting
N/A

Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability

Finnish Institute for Health and Welfare4 sites in 1 country1,200 target enrollmentSeptember 2009

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cognitive Impairment
Sponsor
Finnish Institute for Health and Welfare
Enrollment
1200
Locations
4
Primary Endpoint
Cognitive impairment assessed with a Neuropsychological Test Battery, and Stroop and Trail Making tests.
Status
Active, Not Recruiting
Last Updated
3 years ago

Overview

Brief Summary

This multi-center (6 sites: Helsinki, Kuopio, Oulu, Seinäjoki, Turku, Vantaa) intervention study aims to prevent cognitive impairment, dementia and disability in 60-77 year old persons at an increased dementia risk. The 2-year multi-domain life-style intervention includes nutritional guidance, exercise, cognitive training, increased social activity, and intensive monitoring and management of metabolic and vascular risk factors. The primary outcome is cognitive impairment measured by a sensitive Neuropsychological Test Battery (NTB), and Stroop and Trail Making tests to capture early cognitive impairment typical for both Alzheimer's disease and vascular dementia. We hypothesize that the multi-domain intervention will reduce cognitive impairment in the study group compared to the control group during the initial 2-year intervention period and reduce dementia incidence after the extended follow-up (until at least 300 participants have developed dementia).

Registry
clinicaltrials.gov
Start Date
September 2009
End Date
December 2025
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Finnish Institute for Health and Welfare
Responsible Party
Principal Investigator
Principal Investigator

Miia Kivipelto

Professor

Finnish Institute for Health and Welfare

Eligibility Criteria

Inclusion Criteria

  • aged 60-77 years
  • dementia Risk Score 6 points or more
  • fulfillment of at least one of the following CERAD criteria: i) MMSE: 20-26 points ii) word list memory task (3x10 words): 19 words or less iii) delayed recall: 75% or less

Exclusion Criteria

  • malignant diseases
  • substantial cognitive decline
  • major depression
  • symptomatic cardiovascular disease
  • revascularisation within 1 year
  • severe loss of vision, hearing or communicative ability
  • other conditions inhibiting from safe engagement in the prescribed intervention as judged by the study physician
  • other conditions preventing from cooperation as judged by the study physician

Outcomes

Primary Outcomes

Cognitive impairment assessed with a Neuropsychological Test Battery, and Stroop and Trail Making tests.

Time Frame: 2 years

Secondary Outcomes

  • Disability will be assessed using the ADCS-ADL scale(2 years)
  • Vascular and metabolic risk factors will be assessed with blood pressure and anthropometric measurements, and laboratory analyses of metabolic biomarkers.(2 years)
  • Changes in dietary biomarker levels will be assessed through laboratory testing.(2 years)
  • Depressive symptoms will be assessed using the Zung depression scale.(2 years)
  • Quality of Life will be assessed using the RAND-36 and 15D questionnaires.(2 years)
  • Vascular and metabolic morbidity and mortality will be assessed through questionnaire and register data.(2 years)
  • Utilization of health resources will be assessed using questionnaire and register data.(2 years)

Study Sites (4)

Loading locations...

Similar Trials